2018
DOI: 10.1016/j.ccr.2018.07.012
|View full text |Cite
|
Sign up to set email alerts
|

Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
77
2
8

Year Published

2019
2019
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 145 publications
(90 citation statements)
references
References 131 publications
3
77
2
8
Order By: Relevance
“…The strength of the positive signal at 265 nm decreased by 87.4% for Pu27 DNA and 71.2% for Pu22 DNA, and simultaneously an obvious negative induce CD signal at a wavelength of 295 nm appeared both for Pu27 and Pu22 DNA. These results further confirmed that the complex can interact with c-myc DNA tightly through groove mode, which is similar to the Pu27 binding behavior of [(η 6 For validating the binding stoichiometry of the ruthenium complex with c-myc quadruplex DNA, a continuous variation analysis was used. Fixed the total concentration of ruthenium complex and c-myc G-quadruplex DNA, the fluorescence intensities of the mixed solutions of complex and c-myc DNA with different concentration ratios are different.…”
Section: Binding Behavior Of Ruthenium Complex With C-myc G-quadruplesupporting
confidence: 74%
See 1 more Smart Citation
“…The strength of the positive signal at 265 nm decreased by 87.4% for Pu27 DNA and 71.2% for Pu22 DNA, and simultaneously an obvious negative induce CD signal at a wavelength of 295 nm appeared both for Pu27 and Pu22 DNA. These results further confirmed that the complex can interact with c-myc DNA tightly through groove mode, which is similar to the Pu27 binding behavior of [(η 6 For validating the binding stoichiometry of the ruthenium complex with c-myc quadruplex DNA, a continuous variation analysis was used. Fixed the total concentration of ruthenium complex and c-myc G-quadruplex DNA, the fluorescence intensities of the mixed solutions of complex and c-myc DNA with different concentration ratios are different.…”
Section: Binding Behavior Of Ruthenium Complex With C-myc G-quadruplesupporting
confidence: 74%
“…Ruthenium(II) complexes have attracted extensively attentions as potential alternative drugs for cis-platin in metal-based cancer therapy, due to their excellent binding affinity and luminescene-probe behavior for DNA [1-4], high selectivity to tumor cells and relatively low toxicity toward human normal cells [5][6][7][8]. Research of the last few decades by Chao et al revealed that binding of ruthenium(II) complexes with G-quadruplex DNA plays an important role in their inhibition of tumor cell growth [9][10][11].…”
Section: Introductionmentioning
confidence: 99%
“…The spatial discrimination was identified as an element of the precise geometric positioning of introduced photosensitizer relative to the redox cofactors and the additional prerequisite of the fast electron transfer between photosensitizer and heme cofactor. In view of the growing applications of Ru(II) polypyridyl complexes as photosensitive groups (Brabec and Kasparkova 2018;Lam et al 2016;Mital and Ziora 2018), the results depicted here are valuable for understanding their interactions with protein matrices and enhance our ability to design controlled electron transfer pathways in photo-activated biohybrids molecules.…”
Section: Introductionmentioning
confidence: 97%
“…The versatility of such compounds rely on the possibility to vary the nature of the substituent group in the intercalative ligand, modifying the configuration and electron density distribution of the metal center, allowing to obtain different DNA binding affinities and photo‐cleavage properties. Following this approach, a considerable number of compounds have been reported, including [Ru(bpy) 2 (dppz)] 2+ and [Ru(bpy) 2 (pip)] 2+ (dppz=dipyridophenazine, pip=2‐phenylimidazo[4,5‐f][1,10]phenanthroline), which feature interesting properties as site‐specific luminescent DNA binding agents and abilities to stall the DNA replication of cancer cells as well . However, some critical disadvantages, such as the short lifetime of triplet excited state that reduces the 1 O 2 quantum yield, the low DNA cleavage activity and the poor solubility in physiological media, may represent a serious limit for their further development as PSs in clinical trials .…”
Section: Introductionmentioning
confidence: 99%
“…Following this approach,aconsiderable number of compounds have been reported, including [Ru(bpy) 2 (dppz)] 2 + and [Ru(bpy) 2 (pip)] 2 + (dppz = dipyridophenazine, pip = 2-phenylimidazo[4,5-f] [1,10]phenanthroline), which feature interesting properties as site-specific luminescentD NA binding agentsa nd abilitiest o stall the DNA replication of cancerc ells as well. [13,14] However, some critical disadvantages, such as the short lifetimeo ft riplet excited state that reduces the 1 O 2 quantum yield, the low DNA cleavage activity and the poor solubility in physiological media, may represent as erious limit for their further development as PSs in clinicalt rials. [15] In this context, Ru-polypyridyl complexes featuring charged polyamino chains appended to the heteroaromatic units represent an appealing choice, although, to the best of our knowledge,t hey have not been largely investigated as PDT photosensitizer.…”
Section: Introductionmentioning
confidence: 99%